Significantly lower numbers of LILRA2+, LILRB2+ and LILRB3+ inflammatory cells were detected in RA patients who responded to anti-rheumatic therapy compared to healthy controls, as a result of the partial blocking of LILRA2-mediated secretion of TNF-α (63, 87, 257). Here, LILRB2 is linked to rheumatoid arthritis.